AM-101 impairs the viability of not only lung adenocarcinoma cells, including KRAS and TP53 mutated, but of patient-derived cells of other NSCLC subtypes, including squamous cell and large cell, with IC50 values in the range of 2–4 μM (Figure 1F; Figure S2A). Here, KRAS is linked to non-small cell lung carcinoma.